{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:10:39Z","timestamp":1793297439545,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,8]],"date-time":"2024-05-08T00:00:00Z","timestamp":1715126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eclinm.2024.102661","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T14:07:36Z","timestamp":1716818856000},"page":"102661","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"special_numbering":"C","title":["GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit\u2013harm modelling study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3765-9864","authenticated-orcid":false,"given":"Hannah","family":"Moll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2297-5245","authenticated-orcid":false,"given":"Eliane","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina","family":"Geidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Braun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Beuschlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milo A.","family":"Puhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5400-2448","authenticated-orcid":false,"given":"Henock G.","family":"Yebyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102661_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes \u2013 state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.eclinm.2024.102661_bib2","doi-asserted-by":"crossref","DOI":"10.1177\/20406223221108064","article-title":"Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review","volume":"13","author":"Deng","year":"2022","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.eclinm.2024.102661_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.eclinm.2024.102661_bib4","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes"},{"key":"10.1016\/j.eclinm.2024.102661_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib6","series-title":"FDA approves new medication for chronic weight management","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102661_bib7","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity \u2014 a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib8","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib9","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102661_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101351","article-title":"GLP-1 physiology informs the pharmacotherapy of obesity","volume":"57","author":"Drucker","year":"2022","journal-title":"Mol Metab"},{"key":"10.1016\/j.eclinm.2024.102661_bib11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2024.102661_bib12","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2024.102661_bib13","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib14","series-title":"Tirzepatide","author":"Farzam","year":"2023"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102661_bib15","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/asj\/sjad211","article-title":"Public interest in the off-label use of glucagon-like peptide 1 agonists (ozempic) for cosmetic weight loss: a google trends analysis","volume":"44","author":"Han","year":"2023","journal-title":"Aesthet Surg J"},{"key":"10.1016\/j.eclinm.2024.102661_bib16","article-title":"Wegovy: weight loss drug to be available from GPs in pilot scheme","volume":"381","author":"Iacobucci","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.eclinm.2024.102661_bib17","author":"Jankovi\u0107"},{"key":"10.1016\/j.eclinm.2024.102661_bib18","series-title":"Japan faces GLP-1 shortage as off-label diet use surges","author":"Takagi","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102661_bib19","series-title":"GLP-1 receptor agonists: breaking down the hype and demand","author":"Bonner","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102661_bib20","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: the SURPASS clinical trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.eclinm.2024.102661_bib23","series-title":"Mounjaro. Swissmedic","year":"2022"},{"key":"10.1016\/j.eclinm.2024.102661_bib24","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1093\/jnci\/91.21.1829","article-title":"Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer","volume":"91","author":"Gail","year":"1999","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.eclinm.2024.102661_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M18-1279","article-title":"Finding the balance between benefits and harms when using statins for primary prevention of cardiovascular disease","volume":"170","author":"Yebyo","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib26","first-page":"1","article-title":"Personalising add-on treatment with inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a benefit\u2013harm modelling study","volume":"7500","author":"Yebyo","year":"2021","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.eclinm.2024.102661_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0493-2","article-title":"Benefit-harm analysis and charts for individualized and preference-sensitive prevention: example of low dose aspirin for primary prevention of cardiovascular disease and cancer","volume":"13","author":"Puhan","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jclinepi.2016.02.018","article-title":"Evidence selection for a prescription drug\u2019s benefit-harm assessment: challenges and recommendations","volume":"74","author":"Fain","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.eclinm.2024.102661_bib29","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jval.2019.11.007","article-title":"Informing patient-centered care through stakeholder engagement and highly stratified quantitative benefit\u2013harm assessments","volume":"23","author":"Aschmann","year":"2020","journal-title":"Value Health"},{"key":"10.1016\/j.eclinm.2024.102661_bib30","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1177\/17407745211068549","article-title":"Large-scale prevention trials could provide stronger evidence for decision-makers: opportunities to design and report with a focus on the benefit\u2013harm balance","volume":"19","author":"Aschmann","year":"2022","journal-title":"Clin Trials"},{"key":"10.1016\/j.eclinm.2024.102661_bib31","first-page":"139","article-title":"Benefits and harms of roflumilast in moderate to severe COPD Tsung","volume":"176","author":"Yu","year":"2017","journal-title":"Physiol Behav"},{"key":"10.1016\/j.eclinm.2024.102661_bib32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0140-6736(12)61680-8","article-title":"Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010","volume":"380","author":"Salomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102661_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12872-018-0838-9","article-title":"Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts","volume":"18","author":"Yebyo","year":"2018","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.eclinm.2024.102661_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O\u2019Neil","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102661_bib35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"key":"10.1016\/j.eclinm.2024.102661_bib36","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A\u00a0randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib37","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102661_bib38","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102661_bib39","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"A\u00a0randomized, controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib40","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40264-020-00982-9","article-title":"Benefit-risk assessment of vaccines. Part II: proposal towards consolidated standards of reporting quantitative benefit-risk models applied to vaccines (BRIVAC)","volume":"43","author":"Arlegui","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.eclinm.2024.102661_bib41","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.eclinm.2024.102661_bib42","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib43","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102661_bib44","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight\/obesity: step 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.eclinm.2024.102661_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJMp1504023","article-title":"Placebo effects in medicine","volume":"373","author":"Kaptchuk","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102661_bib46","author":"Beuschlein"},{"key":"10.1016\/j.eclinm.2024.102661_bib47","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eclinm.2024.102661_bib48","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.eclinm.2024.102661_bib49","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2024.102661_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102475","article-title":"Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial","volume":"69","author":"Jensen","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.eclinm.2024.102661_bib51","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12933-023-01800-z","article-title":"Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study","volume":"22","author":"Piccini","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eclinm.2024.102661_bib52","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.eclinm.2024.102661_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.108921","article-title":"GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials","volume":"177","author":"Tsapas","year":"2021","journal-title":"Diabetes Res Clin Pract"}],"updated-by":[{"DOI":"10.1016\/j.eclinm.2026.104022","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000}}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:54:07Z","timestamp":1785912847000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024002402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"alternative-id":["S2589537024002402"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit\u2013harm modelling study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102661","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102661"}}